SBMFF:OTC-Sino Biopharmaceutical Limited (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 1.03

Change

0.00 (0.00)%

Market Cap

USD 19.71B

Volume

100.00

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Company Website : http://www.sinobiopharm.com

Address : Office Tower, Wan Chai, Hong Kong

Employees : 24,328

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.67

52 Week High : 1.45

52 Week Low : 0.78

200 Day Moving Average : 1.14

50 Day Moving Average : 0.94

Shares Held By Insiders : 474.94%

Shares Held by Institutions : 15.9%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

 USD167.99B 29.71 2.87
CSLLY CSL Limited

N/A

 USD96.16B 46.11 26.33
CMXHF CSL Limited

N/A

 USD94.62B 45.29 26.33
GNMSF Genmab A/S

N/A

 USD28.04B 121.29 3.24
UCBJF UCB SA

N/A

 USD19.93B 19.80 17.47
UCBJY UCB SA

N/A

 USD19.87B 19.75 17.47
SBHMY Sino Biopharmaceutical Limited

N/A

 USD19.71B 28.00 2.97
PPTDF PeptiDream Inc

N/A

 USD7.19B 260.99 1.65
IDRSF Idorsia Ltd

N/A

 USD5.36B 130.60 N/A
ABCZF Abcam plc

N/A

 USD5.21B 57.64 114.95

ETFs Containing SBMFF

Symbol Name Weight Mer Price(Change) Market Cap
KURE KraneShares MSCI All Chin.. 0.00 % 0.65 %

N/A

 USD0.17B
CHNA Loncar China BioPharma ET.. 0.00 % 0.79 %

N/A

 USD0.01B
CHNA Loncar China BioPharma ET.. 0.00 % 0.79 %

N/A

 USD0.01B
CHIH Global X MSCI China Healt.. 0.00 % 0.66 %

N/A

 USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.10% 36% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.10% 36% F 46% F
Trailing 12 Months  
Capital Gain 1.64% 39% F 45% F
Dividend Return 0.88% 80% B- 16% F
Total Return 2.53% 39% F 44% F
Trailing 5 Years  
Capital Gain 127.21% 73% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 127.21% 73% C 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 33.03% 63% D 74% C
Dividend Return 3.95% 94% A 71% C-
Total Return 36.98% 66% D 74% C
Risk Return Profile  
Volatility (Standard Deviation) 61.25% 56% F 37% F
Risk Adjusted Return 60.37% 91% A- 88% B+
Market Capitalization 19.71B 97% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.21 35% F 24% F
Price/Book Ratio 3.57 65% D 32% F
Price / Cash Flow Ratio 3.70 13% F 30% F
EV/EBITDA 2.97 63% D 55% F
Management Effectiveness  
Return on Equity 10.06% 85% B 74% C
Return on Invested Capital 12.07% 64% D 74% C
Return on Assets 4.40% 92% A- 82% B-
Debt to Equity Ratio 25.34% 26% F 54% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.67 56% F 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.